Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High vs. Standard Dose Flu Vaccine in Pediatric HSCT
NCT02860039Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 2016
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of influenza virus vaccine, split virion in influenza (2 arms), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Immunogenicity as Measured by the Number of Subjects Who Achieve a 4-fold (or Greater) Rise in Post-vaccination HAI Titers. Started Sep 2016; status: completed.
02
Drugs
influenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02860039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860039.